Anti-SARS-CoV-2 antibody responses in convalescent plasma donors with varying clinical manifestation severity of COVID-19

Jasmina Grujić; Nevenka Bujandrić; Zorana; Nebojša Savić; Vladimir Dolinaj

doi:10.2298/VSP210301094G

Jasmina Grujić Blood Transfusion Institute of Vojvodina, Novi Sad, Serbia; University of Novi Sad, Faculty of Medicine, Department of Internal Medicine, Novi Sad, Serbia
Nevenka Bujandrić Blood Transfusion Institute of Vojvodina, Novi Sad, Serbia; University of Novi Sad, Faculty of Medicine, Department of Internal Medicine, Novi Sad, Serbia
Zorana Blood Transfusion Institute of Vojvodina, Novi Sad, Serbia; University of Novi Sad, Faculty of Medicine, Department of Internal Medicine, Novi Sad, Serbia
Nebojša Savić University Clinical Center of Serbia, Clinic for Vascular and Endovascular Surgery, Department of Transfusion Medicine, Belgrade, Serbia
Vladimir Dolinaj University Clinical Center of Vojvodina, Department of Anesthesiology, Novi Sad, Serbia

DOI: https://doi.org/10.2298/VSP210301094G

Ključne reči: antitela, stvaranje;, krv, davaoci;, COVID-19 seroterapija;, imunizacija, pasivna;, plazma.

Sažetak

Uvod/Cilj. Plazma koja sadrži visok titar antitela na SARS-CoV-2, donirana od osoba koje su se oporavile od COVID-19, ima potencijal da se koristi kao inicijalna terapija kod obolelih u vidu pasivne imunizacije. Poseban izazov predstavlja izbor odgovarajućih davalaca plazme. Cilj rada bio je sukcesivno praćenje titra antitela u donacijama plazme i ispitivanje korelacije između titra antitela i težine kliničke slike koju su davaoci imali tokom bolesti. Metode. Retrospektivna studija sprovedena je od 1. maja do 31. oktobra 2020. godine na Institutu za transfuziju krvi Vojvodine. Davaoci su morali da ispune određene kriterijume za uključivanje u studiju: dokazana infekcija SARS-CoV-2, prisutna antitela na SARS-CoV-2 u serumu/plazmi, ispunjavanje opštih kriterijuma za izvođenje plazmafereze i referentne vrednosti laboratorijskih nalaza. Rezultati. Tokom studije prikupljeno je 651 jedinica aferezne plazme podeljenih u dve jednake doze. Plazmu je doniralo 311 COVID-19 rekonvalescenata, uključujući 208 (66,9%) muškaraca i 103 (33,1%) žena. Davalaca plazme sa asimptomatskom infekcijom bilo je 15 (4,8%), sa blagim oblikom bolesti 235 (75,6%), sa umereno teškim oblikom bolesti 45 (14,5%), sa teškim oblikom bolesti 16 (5,1%). Osobe sa kritičnim oblikom bolesti nisu donirale plazmu. Antitela klase IgG na SARS-CoV-2 bila su prisutna kod davalaca plazme više od šest meseci nakon bolesti, pri čemu su davaoci plazme koji su imali težu kliničku sliku COVID-19 imali stabilne vrednosti antitela tokom dužeg vremenskog perioda. Pearson-ova korelacija težine kliničke slike i titra antitela nije potvrdila njihovu statistički značajnu povezanost. Zaključak. Antitela klase IgG na SARS-CoV-2 bila su prisutna kod davalaca plazme više od šest meseci nakon bolesti. Iako nije nađena statistički značajna korelacija između titra antitela klase IgG na SARS-CoV-2 i težine kliničke slike COVID-19, utvrđeno je da se kod bolesnika koji su imali težu kliničku sliku bolesti, stabilan titar antitela održavao tokom dužeg vremenskog perioda.

Reference

1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020; 382(13): 1199‒207.

2. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed 2020; 91(1): 157‒60.

3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507–13.

4. WHO Coronavirus Disease (COVID-19) Dashboard. Available from: https://covid19.who.int/

5. Recommendations for investigational COVID-19 convalescent plasma-Food and Drug Administration; 2020. Available from: https://www.fda.gov/vaccines-blood-biologics/investigational
/>-new-drug-ind-or-device-exemption-ide-process-cber/recomm
endations-investigational-covid-19-convalescent-plasma.

6. World Health Organization. Guidance on maintaining a safe and adequate blood supply during the coronavirus disease 2019 (‎‎COVID-19)‎‎ pandemic and on the collection of COVID-19 convalescent plasma: interim guidance; 2020 Available from: https://apps.who.int/iris/handle/10665/333
/>182.

7. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest 2020; 130(4): 1545‒8.

8. Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, et al. The Effect of Convalescent Plasma Therapy on COVID-19 Patient Mortality: Systematic Review and Meta-analysis. Mayo Clin Proc 2021; 96(5): 1262‒75.

9. Liu A, Li Y, Wan Z, Wang W, Lei X, Lv Y. Seropositive prevalence of antibodies against SARS-CoV-2 in Wuhan, China. JAMA Netw Open 2020; 3(10): e2025717.

10. Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, et al. Covid-19-neutralizing antibodies predict disease severity and survival. Cell 2021; 184(2): 476‒88.e11.

11. Koutsakos M, Rowntree LC, Hensen L, Chua BY, Van de Sandt CE, Habel JR, et al. Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Rep Med 2021; 2(3): 100208.

12. Ho MS, Chen WJ, Chen HY, Lin SF, Wang MC, Di J, et al. Neutralizing antibody response and SARS severity. Emerg Infect Dis 2005; 11(11): 1730‒7.

13. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis 2020; 26(7): 1478‒88.

14. Klein SL, Pekosz A, Park HS, Ursin RL, Shapiro JR, Benner SE, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest 2020; 130(11): 6141‒50.

15. Mendoza RP, Fyke W, Daniel D, Gabutan E, Das B, Bajaj H, et al. Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes. Hum Immunol 2021; 82(4): 255‒63.

16. Pavlova IP, Nair SS, Kyprianou N, Tewari AK. The Rapid Coronavirus Antibody Test: Can We Improve Accuracy? Front Med (Lausanne) 2020; 7: 569.

17. Fridley GE, Le H, Yager P. Highly sensitive immunoassay based on controlled rehydration of patterned reagents in a 2-dimensional paper network. Anal Chem 2014; 86(13): 6447‒53.

18. Fu E, Liang T, Spicar-Mihalic P, Houghtaling J, Ramachandran S, Yager P. Two-dimensional paper network format that enables simple multistep assays for use in low-resource settings in the context of malaria antigen detection. Anal Chem 2012; 84(10): 4574‒9.

19. Gutierrez-Cobos A, Frutos SG, Garcia DD, Lara EN, Carrion AY, Garcia-Rodrigo LF, et al. Evaluation of diagnostic accuracy of 10 serologial assays for detection of SARS-CoV-2 antibodies. Eur J Clin Microbiol Infect Dis. 2020;24:1-7.

20. Szabó Z, Szabó T, Bodó K, Kemenesi G, Földes F, Kristóf K, et al. Comparison of virus neutralization activity and results of 10 different anti-SARS-CoV-2 serological tests in COVID-19 recovered plasma donors. Pract Lab Med 2021; 25: e00222.

21. Dulipsingh L, Ibrahim D, Schaefer EJ, Crowell R, Diffenderfer MR, Williams K, et al. SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma. Transfus Apher Sci 2020; 59(6): 102922.

22. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med 2020; 383(18):1724–34.

23. Lumley SF, O'Donnell D, Stoesser E, Matthews PC, Howarth A, Hatch SB, et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med 2020; 384(6): 533–40.

24. Priyanka, Choudhary OP, Singh I. Protective immunity against COVID-19: Unravelling the evidences for humoral vs. cellular components. Travel Med Infect Dis 2021; 39: 101911.

25. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020; 38(1): 1‒9.

26. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020; 26(8): 1200‒4.

27. Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol 2020; 5(52):eabe0367.

28. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021; 371(6529): eabf4063.

29. Balint B, Todorović Balint M, Anrić Z, Jovičić M, Blagojević G, Čolić M. Long-term antibody-response monitoring following primary exposure to SARS-COV-2 and afterward mRNA COVID-19 vaccination: A case report. Vojnosanitet Pregl 2021; 78(3): 379‒81.

30. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to SARS‐CoV‐2 spike antigens in COVID‐19 patients. Sci Immunol 2020; 5(52): eabe5511.

31. Thieme CJ, Anft M, Paniskaki K, Blazquez-Navarro A, Doevelaar A, Seibert FS, et al. Robust T cell response toward spike, membrane, and nucleocapsid SARS‐CoV‐2 proteins is not associated with recovery in critical COVID‐19 patients. Cell Reports Med 2020; 1(6): 100092.

32. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hpffman C, Hausner MA, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med 2020; 383(11): 1085–87.

33. Kong WH, Zhao R, Zhou JB, Wang F, Kong DG, Sun JB, et al. Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity. Virol Sin 2020; 35(6): 752‒7.

34. Zhang B, Zhou X, Zhu C, Song Y, Feng F, Qiu Y, et al. Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19. Front Mol Biosci 2020; 7: 157.

35. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis 2020; 71(16): 2027‒34.

36. Röltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Najeeb J, et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol 2020; 5(54): eabe0240.

37. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020; 26(6): 845‒8.

38. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130(5): 2620‒9.

Anti-SARS-CoV-2 antitela kod rekonvalescentnih davalaca plazme sa različitom težinom kliničke slike COVID-19

Sažetak

Reference